meningitis

(redirected from Menactra)
Also found in: Thesaurus, Medical, Encyclopedia.

men·in·gi·tis

 (mĕn′ĭn-jī′tĭs)
n.
Inflammation of the meninges of the brain and the spinal cord, most often caused by a bacterial or viral infection and characterized by fever, vomiting, intense headache, and stiff neck.

men′in·git′ic (-jĭt′ĭk) adj.

meningitis

(ˌmɛnɪnˈdʒaɪtɪs)
n
(Pathology) inflammation of the membranes that surround the brain or spinal cord, caused by infection
meningitic adj

men•in•gi•tis

(ˌmɛn ɪnˈdʒaɪ tɪs)

n.
inflammation of the meninges, esp. of the pia mater and arachnoid, caused by a bacterial or viral infection and characterized by high fever, severe headache, and stiff neck or back muscles.
[1820–30]
men`in•git′ic (-ˈdʒɪt ɪk) adj.

men·in·gi·tis

(mĕn′ĭn-jī′tĭs)
Inflammation of the membranes (meninges) that enclose the brain and spinal cord, usually resulting from a bacterial infection.

meningitis

Inflammation of the linings of the brain (meninges) usually caused by a virus.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.meningitis - infectious disease characterized by inflammation of the meninges (the tissues that surround the brain or spinal cord) usually caused by a bacterial infectionmeningitis - infectious disease characterized by inflammation of the meninges (the tissues that surround the brain or spinal cord) usually caused by a bacterial infection; symptoms include headache and stiff neck and fever and nausea
choriomeningitis - a cerebral meningitis with cellular infiltration of the meninges
infectious disease - a disease transmitted only by a specific kind of contact
brain fever, cerebrospinal fever, cerebrospinal meningitis, epidemic meningitis - meningitis caused by bacteria and often fatal
cerebromeningitis, encephalomeningitis, meningoencephalitis - inflammation of the brain and spinal cord and their meninges
leptomeningitis - inflammation of the leptomeninges
Translations
إلْتِهاب السَّحاياالْتِهَابُ الْسَّحَايَا
meningitidazánět mozkových blan
meningitis
aivokalvontulehdus
meningitis
agyhártyagyulladás
heilahimnubólga
髄膜炎
뇌수막염수막염
meningitas
meningīts
zápal mozgových blán
hjärnhinneinflammation
เยื่อหุ้มสมองอักเสบ
viêm màng não

meningitis

[ˌmenɪnˈdʒaɪtɪs] Nmeningitis f inv

meningitis

[ˌmɛnɪndˈʒaɪtɪs] nméningite f

meningitis

meningitis

[ˌmɛnɪnˈdʒaɪtɪs] nmeningite f

meningitis

(meninˈdʒaitis) noun
a serious disease in which there is inflammation of the membranes round the brain or spinal cord.

meningitis

الْتِهَابُ الْسَّحَايَا meningitida meningitis Hirnhautentzündung μηνιγγίτιδα meningitis aivokalvontulehdus méningite meningitis meningite 髄膜炎 수막염 meningitis hjernehinnebetennelse zapalenie opon mózgowych meningite менингит hjärnhinneinflammation เยื่อหุ้มสมองอักเสบ menenjit viêm màng não 脑膜炎

men·in·gi·tis

n. meningitis, infl. de las meninges cerebrales o espinales;
cryptococcal ______ criptocócica;
meningcoccal ______ meningocócica;
viral ______ viral.

meningitis

n meningitis f
References in periodicals archive ?
However, if Menactra is used, give it at least 4 weeks after com pleting all pneumococcal conjugate vaccine doses and either before or concomitantly with diphtheria and tetanus toxoid and acellular pertussis vaccine (DTaP).
A second vaccine for meningococcal disease (Menactra) is being studied in the Menactra Vaccine Pregnancy Registry (800-822-2463 / www.
Sanofi Pasteur vaccine sales were 628 million [euro], down 4%, reflecting a phasing effect in Pentaxim deliveries in Emerging Markets, offset by strong sales for Imovax in Japan and Menactra in the previous year period.
Approved in the US in 1981 and Australia in 1994, Menomune was among the first available vaccines against meningococcal disease and was the standard of care in the US until the introduction of Menactra in 2005.
Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.
M2 PHARMA-December 4, 2012-Sanofi Pasteur Canada announces approval by Health Canada of Menactra Meningococcal Conjugate Vaccine for infants from nine months(C)2012 M2 COMMUNICATIONS
M2 EQUITYBITES-December 4, 2012-Sanofi Pasteur Canada announces approval by Health Canada of Menactra Meningococcal Conjugate Vaccine for infants from nine months(C)2012 M2 COMMUNICATIONS http://www.
Food and Drug Administration (FDA) has approved the use of Sanofi Pasteur's bacterial meningitis vaccine Menactra in children as young as 9 months.
The Ontario government will supply the vaccine, Menactra, for use in the voluntary school-based immunization program for Grade seven students.
But representatives from Menactra manufacturer Sanofi Pasteur assured the committee that the company's total vaccine supply from January 2007 to September 2007 is on track to exceed 6 million doses resulting from surplus carried over from 2006 when the vaccine was deferred in the younger adolescents.
Menactra, developed by Sanofi Pasteur, is expected to offer longer protection than earlier meningitis vaccines.
Aventis (Swiftwater, PA), part of the Sanofi-Aventis Group, announced that the Vaccines and Related Biological Products Advisory Committee of the United States Food and Drug Administration (FDA) voted unanimously to recommend licensure of Menactra (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate) Vaccine for protection against invasive meningococcal disease in adolescents and adults aged 11-55 years.